Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy

WANG Zhigao; FANG Qiqi; GAO Fei; LI Qingxia

doi:10.3971/j.issn.1000-8578.2020.19.1400

Cancer Research on Prevention and Treatment > 2020 > 47(11): 818-816. > DOI: 10.3971/j.issn.1000-8578.2020.19.1400

WANG Zhigao, FANG Qiqi, GAO Fei, LI Qingxia. Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 818-816. DOI: 10.3971/j.issn.1000-8578.2020.19.1400

Citation:

PDF (4065 KB)

Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy

Fourth Department of Oncology, Hebei General Hospital, Shijiazhuang 050000, China

More Information

Corresponding author:
LI Qingxia, E-mail: lqx73@163.com
Received Date: November 07, 2019
Revised Date: June 17, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

With the in-depth study of tumor immune microenvironment, immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors have achieved promising results in tumor treatment. However, the treatment response rate is low with immunotherapy alone. Integrative therapy is the development trend of tumor therapy. The combined treatment strategies of PD-1/PD-L1 inhibitors with chemotherapy, radiotherapy, TKI, antiangiogenic drugs, etc. are being actively explored. This paper reviews the mechanism and progress of related combined regimens.
- Immune checkpoint inhibitor,
- Tumor,
- Combined treatment

FullText(HTML)

References (45)

References

[1]	Sieggel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69（1）: 7-34. doi: 10.3322/caac.21551
[2]	Galluzzi L, Vacchelli E, Bravo-San Pedro JM, et al. Classification of current anticancer immunotherapies[J]. Oncotarget, 2014, 5（24）: 12472-12508. doi: 10.18632/oncotarget.2998
[3]	Frey AB. Suppression of T cell responses in the tumor microenvironment[J]. Vaccine, 2015, 33（51）: 7393-7400. doi: 10.1016/j.vaccine.2015.08.096
[4]	Gettinger S, Horn L, Jackman D, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study[J]. J Clin Oncol, 2018, 36（17）: 1675-1684. doi: 10.1200/JCO.2017.77.0412
[5]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer[J]. N Engl J Med, 2016, 375（19）: 1823-1833. doi: 10.1056/NEJMoa1606774
[6]	Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice[J]. J Clin Invest, 2010, 120（4）: 1111-1124. doi: 10.1172/JCI40269
[7]	Jackaman C, Majewski D, Fox SA, et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8（+） T cells in vivo[J]. Cancer Immunol Immunother, 2012, 61（12）: 2343-2356. doi: 10.1007/s00262-012-1307-4
[8]	Galluzzi L, Zitvogel L, Kroemer G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy[J]. Cancer Immunol Res, 2016, 4（11）: 895-902. doi: 10.1158/2326-6066.CIR-16-0197
[9]	Wan S, Pestka S, Jubin RG, et al. Chemotherapeutics and radiation stimulate MHC classⅠexpression through elevated interferon-beta signaling in breast cancer cells[J]. PLoS One, 2012, 7（3）: e32542. doi: 10.1371/journal.pone.0032542
[10]	Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer[J]. Cell Death Differ, 2014, 21（1）: 15-25. doi: 10.1038/cdd.2013.67
[11]	Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer[J]. Cancer Res, 2015, 75（23）: 5034-5045. doi: 10.1158/0008-5472.CAN-14-3098
[12]	Nisticò P, Capone I, Palermo B, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients[J]. Int J Cancer, 2009, 124（1）: 130-139.
[13]	West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer （IMpower130）: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20（7）: 924-937. doi: 10.1016/S1470-2045（19）30167-6
[14]	Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378（22）: 2078-2092. doi: 10.1056/NEJMoa1801005
[15]	Paz-Ares LG, Luft A, Tafreshi A, et al. Phase 3 study of carboplatin-paclitaxel/ nab-paclitaxel（Chemo） with or without pembrolizumab（Pembro） for patients（Pts） with metastatic squamous（Sq） non-small cell lung cancer（NSCLC）[J]. J Clin Oncol, 2018, 36（15_suppl）: 105. doi: 10.1200/JCO.2018.36.15_suppl.105
[16]	Feld E, Harton J, Meropol NJ, et al. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancerl[J]. Eur Urol, 2019, 76（4）: 524-532. doi: 10.1016/j.eururo.2019.07.032
[17]	Golden EB, Pellicciotta I, Demaria S, et al. The convergence of radiation and immunogenic cell death signaling pathways[J]. Front Oncol, 2012, 2: 88.
[18]	Walle T, Monge RM, Cerwenka A, et al. Radiation effects on antitumor immune responses: current perspectives and challenges[J]. Ther Adv Med Oncol, 2018, 10: 1758834017742575.
[19]	徐唐鹏, 胡梦雪, 许斌, 等.远隔效应的作用机制及临床进展[J].肿瘤学杂志, 2019, 25（3）: 202-205. Xu TP, Hu MX, Xu bin, et al. The mechanism and clinical progress of distant effect[J]. Zhong Liu Xue Za Zhi, 2019, 25（3）: 202-205.
[20]	Takeshima T, Chamoto K, Wakita D, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy[J]. Cancer Res, 2010, 70（7）: 2697-2706. doi: 10.1158/0008-5472.CAN-09-2982
[21]	Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124（2）: 687-695. doi: 10.1172/JCI67313
[22]	杨柳, 朱曦龄, 黎功.放疗联合免疫抗肿瘤治疗策略的研究进展[J].中华放射医学与防护杂志, 2017, 37（1）: 73-77. Yang L, Zhu XL, Li G. The research progress for anti-tumor strategies of radiotherapy and immunotherapy[J]. Zhonghua Fang She Yi Xue Yu Fang Hu Za Zhi, 2017, 37（1）: 73-77.
[23]	Newton JM, Hanoteau A, Liu HC, et al. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition[J]. J Immunother Cancer, 2019, 7（1）: 216.
[24]	Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J]. Int J Radiat Oncol Biol Phys, 2013, 86（2）: 343-349. doi: 10.1016/j.ijrobp.2012.12.025
[25]	Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of abscopal effect in a patient with melanoma[J]. N Eng J Med, 2012, 366（10）: 925-931. doi: 10.1056/NEJMoa1112824
[26]	Levy A, Massard C, Soria JC, et al. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase1/2 trial[J]. Eur J Cancer, 2016, 68: 156-162. doi: 10.1016/j.ejca.2016.09.013
[27]	Kim JE, Patel MA, Mangraviti A, et al. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas[J]. Clin Cancer Res, 2017, 23（1）: 124-136. doi: 10.1158/1078-0432.CCR-15-1535
[28]	Jain RK. Determinants of tumor blood flow: a review[J]. Cancer Res, 1988, 48（10）: 2641-2658.
[29]	Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal[J]. J Clin Invest, 1999, 103（2）: 159-165.
[30]	Ye W. The complexity of translating anti-angiogenesis therapy from basic science to the clinic[J]. Dev Cell, 2016, 37（2）: 114-125.
[31]	Min L, Ling W, Hua R, et al. Anti-angiogeic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential[J]. Mol Med Rep, 2016, 13（3）: 2518-2526. doi: 10.3892/mmr.2016.4854
[32]	Arjaans M, Schrader CP, Oosting SF, et al. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside[J]. Oncotarget, 2016, 7（16）: 21247-21258. doi: 10.18632/oncotarget.6918
[33]	Huang Y, Stylianopoulos T, Duda DG, et al. Benefits of vascular normalization are dose and time dependent-letter[J]. Cancer Res, 2013, 73（23）: 7144-7146. doi: 10.1158/0008-5472.CAN-13-1989
[34]	Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer[J].Cancer Res, 2013, 73（2）: 539-549.
[35]	Shigeta K, Datta M, Hato T, et al. Dual Programmed Death Receptor-1 and Vasclar Endothelial Growth Factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in Hepatocellular Carcinoma[J]. Hepatology, 2020, 71（4）: 1247-1261. doi: 10.1002/hep.30889
[36]	Xu J, Zhang Y, Jia R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res, 2019, 25（2）: 515-523. doi: 10.1158/1078-0432.CCR-18-2484
[37]	Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer[J]. Oncologist, 2017, 22（1）: 81-88. doi: 10.1634/theoncologist.2016-0189
[38]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378（22）: 2093-2104. doi: 10.1056/NEJMoa1801946
[39]	Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J]. Lancet Oncol, 2016, 17（3）: 299-308. doi: 10.1016/S1470-2045（15）00544-6
[40]	Nan X, Xie C, Yu X, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer[J]. Oncotarget, 2017, 8（43）: 75712-75726. doi: 10.18632/oncotarget.20095
[41]	Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M positive lung cancer[J]. N Engl J Med, 2017, 376（7）: 629-640. doi: 10.1056/NEJMoa1612674
[42]	Jiang L, Guo F, Liu X, et al. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC[J]. Sci Rep, 2019, 9（1）: 3705.
[43]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373（17）: 1627-1639. doi: 10.1056/NEJMoa1507643
[44]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer（KEYNOTE-010）: a randomised controlled trial[J]. Lancet, 2016, 387（10027）: 1540-1550. doi: 10.1016/S0140-6736（15）01281-7
[45]	Ott PA, Bang YJ, Piha-Paul PA, et al. T-cell-inflamed Gene-Expression Profile, Programmed Death Ligand, Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumal Across 20 Cancers: KEYNOTE-028[J]. J Clin Oncol, 2019, 37（4）: 318-327. doi: 10.1200/JCO.2018.78.2276

Cited By

Cited by

Periodical cited type(5)

1.	卯云烨，王安，葛祥伟，翟今朝，李涛，汪进良. 免疫治疗联合局部治疗在老年晚期NSCLC患者中的疗效研究. 中国现代医生. 2025(11): 39-41 .
2.	赵磊，王先珍，马玲云. 循证预防性护理对原发性肿瘤免疫治疗患者的影响. 中国医药导报. 2023(10): 186-189 .
3.	黄细香，蔡晓璇，王天吉，黄妙恩，李立，吕应年. 海发菜提取物脱镁叶绿素酸盐A对六种癌细胞的光毒性. 肿瘤防治研究. 2022(08): 780-785 . 本站查看
4.	钟璇. 基因检测技术在肿瘤免疫检查点抑制剂应用中的研究进展. 黑龙江科学. 2021(18): 74-75 .
5.	陈焕樑，徐一清，刘勇. 抗血管生成治疗影响肿瘤免疫治疗的研究进展. 肿瘤预防与治疗. 2021(10): 948-954 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1866) PDF downloads (3015) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy

Abstract

References

Cited by

Periodical cited type(5)

Other cited types(0)

Catalog

Download Center

Links

Contact Us

Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy

Abstract

References

Cited by

Periodical cited type(5)

Other cited types(0)

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content